Compare LADR & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | EVO |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2013 | N/A |
| Metric | LADR | EVO |
|---|---|---|
| Price | $10.06 | $2.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.00 | $7.00 |
| AVG Volume (30 Days) | ★ 529.6K | 127.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.36 | N/A |
| Revenue Next Year | $17.60 | $7.13 |
| P/E Ratio | $19.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.68 | $2.48 |
| 52 Week High | $11.92 | $4.80 |
| Indicator | LADR | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 23.63 |
| Support Level | N/A | N/A |
| Resistance Level | $11.37 | $3.78 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 21.64 | 0.00 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.